



Agenda Item No:	14
------------------------	-----------

Report to:	Humber & North Yorkshire Integrated Care Board
Date of Meeting:	10 July 2024
Subject:	Board Committees Assurance and Escalation Reports
Director Sponsor:	Karina Ellis, Executive Director of Corporate Affairs
Author:	Mike Napier, Director of Governance & Board Secretary Sasha Sencier, Head of Governance and Development
STATUS OF THE REPORT:	
Approve <input type="checkbox"/> Discuss <input type="checkbox"/> Assurance <input checked="" type="checkbox"/> Information <input checked="" type="checkbox"/> A Regulatory Requirement <input type="checkbox"/>	

SUMMARY OF REPORT:

In accordance with the revised reporting arrangements previously agreed by the Board, this report sets out the consolidated summaries for each committee of the Board that has met in the time since the previous Board meeting. A rolling programme of reports will be submitted to the Board in accordance with the committee calendar and as soon as practicable following each committee meeting.

The summaries are provided to a consistent format and report by exception on:

- Matters and/or risks to bring to the attention of the Board, and
- Matters the committee was able to take positive assurance on or where additional information was required.

For July 2024, the following committee reports are attached within the supplementary information. Matters for the attention of the Board are summarised below.

Ref	Committee	Meeting Date	Matters for the attention of the Board
A	Remuneration Committee	10 June	<ul style="list-style-type: none"> • There are no alerts to escalate to the Board. • There are three other matters to advise/assure the Board on.
B	Workforce Board (Workforce Committee)	17 June	<ul style="list-style-type: none"> • There are no alerts to escalate to the Board. • There are four other matters to advise/assure the Board on.
C	Audit Committee	20 June	<ul style="list-style-type: none"> • There is one alerts to escalate to the Board. <ul style="list-style-type: none"> - a report at its next meeting setting out the risks, and their mitigations, associated with the potential migration of the ICB to a cloud-based financial management / accounting system as part of a national programme.

D	Finance, performance & Delivery Committee	24 June	<ul style="list-style-type: none"> • There are two alerts to escalate to the Board. <ul style="list-style-type: none"> - Whilst still early in the financial year a discussion took place around engagement with the wider ICS on how HNY approaches financial reporting for 24/25, delivers the agreed financial plan, and moves towards longer term sustainability. - An escalated conversation has been scheduled with Chief Executive and Director of Finance colleagues across the system to discuss on 1 July. Actions flowing from this discussion will feed into the Board and FPD in due course. • There are seven other matters to advise/assure the Board on.
E	ICP	26 June	<ul style="list-style-type: none"> • There are two alerts to escalate to the Board. The ICP noted: <ul style="list-style-type: none"> - the upcoming Junior Doctor strikes and the ballot released in the public domain by the BMA regarding GP industrial action. - the impact of the cyber security incident in London. • There are eight other matters to advise/assure the Board on.
F	Pharmaceutical Services Regulations Committee (PSRC)	26 June	<ul style="list-style-type: none"> • There are no alerts to escalate to the Board. • There are two other matters to advise /assure the Board on.

Finally, the feedback summary to committees from the June Board meeting are detailed at the end of this cover report.

RECOMMENDATIONS:

Members are asked to:

- Note the content of the Committee Assurance and Escalation Reports.

ICB STRATEGIC OBJECTIVE

Leading for Excellence	<input checked="" type="checkbox"/>
Leading for Prevention	<input checked="" type="checkbox"/>
Leading for Sustainability	<input checked="" type="checkbox"/>
Voice at the Heart	<input checked="" type="checkbox"/>

IMPLICATIONS	
Finance	The Finance, Performance and Delivery Committee is responsible for overseeing, monitoring, and reviewing the stewardship of the finances, investments and sustainability of the ICB, including planning, financial performance, capital expenditure and the delivery of the informatics and estates, facilities and capital development annual plans
Quality	The Quality Committee provide the ICB with assurance that is delivering its functions in a way that secures continuous improvement in the quality of services, against each of the dimensions of quality set out in the Shared Commitment to Quality and enshrined in the Health and Care Act 2021. This includes reducing inequalities in the quality of care.
HR	The Workforce Committee (aka Workforce Board) provide strategic system oversight of the development and delivery of the Humber and North Yorkshire People Strategy and associated HNY people focused workstreams
Legal / Regulatory	The ICB Constitution and Standing Orders details that Committees of the Board are required to submit agreed key messages of each of its meetings, for information, to the Board.
Data Protection / IG	There are no direct data protection / IG implications relating to this paper. The Audit Committee receives regular updates on IG compliance (including uptake & completion of data security training), data breaches and any related issues and risks.
Health inequality / equality	The Clinical and Professional Committee provides population health led, strategic and collaborative clinical and professional oversight across the NHS Humber and North Yorkshire Integrated Care Board and support the Partnership to achieve its vision of helping the population to 'start well, live well, age well and end life well.' The Population Health & Prevention Committee oversees the ICB's key ambition to improve outcomes in population health and healthcare.
Conflict of Interest Aspects	No conflicts of interest are identified in relation to this paper. The Audit Committee oversees that the ICB's policy, systems and processes for the management of conflicts, (including gifts and hospitality and bribery) are effective including receiving reports relating to non-compliance with the ICB policy and procedures relating to conflicts of interest.
Sustainability	There are no sustainability implications relating to this paper.

ASSESSED RISK:

The ICB has a statutory and regulatory obligation to ensure that systems of control are in place, to minimise the impact of all types of risk.

MONITORING AND ASSURANCE:

The board remains accountable for all functions, including those that it has delegated to committees and, therefore, appropriate reporting and assurance arrangements are in place and documented in the terms of reference of each Committee.

ENGAGEMENT:

A wide variety of ICB subject matter specialists, senior officers and the ICB Board have been engaged in the development of this paper.

REPORT EXEMPT FROM PUBLIC DISCLOSURE

No Yes

**June 2024
Board Feedback Summary to Committees**

Committee	Alert Summary to the Board	Feedback from Board to Committee
Workforce Board (Workforce Committee)	<ul style="list-style-type: none"> • There are no alerts to escalate to the Board. 	No feedback required
Digital Strategy Committee	<ul style="list-style-type: none"> • There is one alert to escalate to the Board: <ul style="list-style-type: none"> - The Terms of Reference for 24/25 were agreed and are with the Board for approval. The governance arrangements in digital sub-groups is currently being finalised. 	No feedback required
Clinical and Professional Committee	<ul style="list-style-type: none"> • There is one alert to escalate to the Board: <ul style="list-style-type: none"> - Data shows that decisions made regarding secondary care ophthalmology medication have not translated into change. 	No feedback required
IRIS Committee	<ul style="list-style-type: none"> • There are two alerts to escalate to the Board: <ul style="list-style-type: none"> - Decision made to create a shared HNY ICB Continuous Improvement Team under IRIS - Committee terms of reference are still being revised and are expected to come to the Board for approval in September 2024. 	No feedback required
Pharmaceutical Services Regulations Committee (PSRC)	<ul style="list-style-type: none"> • There are no alerts to escalate to the Board. 	No feedback required

END.